Focus on epithelial ovarian cancer

Slides:

Advertisements

Similar presentations

“Taking Care of Tomorrows Patient Better than Today”… the Future is Now Set A1 – Title Slide David O’Malley, M.D.

Advertisements

‍‍‍‍Chemotherapy in epithelial ovarian cancer. Dr.Azarm.

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.

A case report of locally advanced triple negative breast cancer showing pathological complete response to weekly paclitaxel with bevacizumab treatment.

Potential Molecular Mechanisms for Improved Prognosis and Outcome with Neoadjuvant Chemotherapy Prior to Laparoscopical Radical Hysterectomy for Patients.

National High Magnetic Field Laboratory

Volume 146, Issue 7, Pages e3 (June 2014)

Lack of Evidence From a Transgenic Mouse Model that the Activation and Migration of Melanocytes to the Epidermis after Neonatal UVR Enhances Melanoma.

Deregulation of SLIT2-Mediated Cdc42 Activity Is Associated with Esophageal Cancer Metastasis and Poor Prognosis Ruo-Chia Tseng, PhD, Jia-Ming Chang,

Efficacy and Safety of Nimotuzumab Plus Radiotherapy With or Without Cisplatin-Based Chemotherapy in an Elderly Patient Subgroup (Aged 60 and Older) With.

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

Volume 138, Issue 3, Pages e1 (March 2010)

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer Wolf Köster, MD, Andrea Heider, MD, Norbert.

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

APRIL promotes B-1 cell-associated neoplasm

Intracranial Tumor Cell Migration and the Development of Multiple Brain Metastases in Malignant Melanoma Trude G. Simonsen, Jon-Vidar Gaustad, Einar.

Covering the Cover Gastroenterology

Focus on epithelial ovarian cancer

Antitumor activity of BAY in patient-derived tumor models.

Volume 146, Issue 7, Pages e3 (June 2014)

Digging Deep: High Output Heart Failure in Renal Cell Carcinoma

Rayburn Rego, MD, Shyam Dang, MD, Catherine Lewis, MD

Co-targeting c-Met and COX-2 Leads to Enhanced Inhibition of Lung Tumorigenesis in a Murine Model with Heightened Airway HGF Laura P. Stabile, PhD, Mary.

Volume 1, Issue 1, Pages (February 2002)

Retrospective Review of Efficacy of Radiofrequency Ablation for Treatment of Colorectal Cancer Liver Metastases From a Canadian Perspective Benjamin.

JNK signaling mediates mammary tumor growth and metastasis to lungs

Takeshi Isobe, MD, PhD, Amir Onn, MD, Daniel Morgensztern, MD, Jörg J

Capture of CK+ and CK− complex aneuploid CTCs in breast, ovarian, or colorectal cancer. Capture of CK+ and CK− complex aneuploid CTCs in breast, ovarian,

SPP1 and TNC promote chemoresistance

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Volume 126, Issue 5, Pages (May 2004)

Overall survival in the IFCT trial comparing a single agent therapy arm (vinorelbine or gemcitabine) and the doublet carboplatin plus weekly paclitaxel.

Morgan D. Schulz, MD, Kimberly Ann V. Zubris, PhD, Jacqueline E

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.

13C/31P MRS Metabolic Biomarkers of Disease Progression and Response to AAV Delivery of hGAA in a Mouse Model of Pompe Disease Celine Baligand, Adrian.

Animal Models of Melanoma

Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab in the Treatment of Patients with Extensive-Stage Small-Cell Lung Cancer David R. Spigel,

miR-210 Is a Prognostic Marker in Clear Cell Renal Cell Carcinoma

Preclinical Profile of Zoledronic Acid in Prostate Cancer Models

Caroline H. Siegel, MD, Richard S. Finn, MD, Michael G. Ho, MD

Volume 2, Issue 6, Pages (December 2002)

Molecular Imaging of the Pancreas in Small Animal Models

A Transposon-Based Analysis of Gene Mutations Related to Skin Cancer Development Rita M. Quintana, Adam J. Dupuy, Ana Bravo, M Llanos Casanova, Josefa.

High Expression of p300 Has an Unfavorable Impact on Survival in Resectable Esophageal Squamous Cell Carcinoma Yong Li, MD, Hao-Xian Yang, MD, Rong-Zhen.

The transcriptional repressor Snail promotes mammary tumor recurrence

Ruth H. Keogh, Sanja Stanojevic Journal of Cystic Fibrosis

A Phase 2 Randomized Trial of Paclitaxel and Carboplatin with or without Panitumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

Seiko Ishida, Frank McCormick, Karen Smith-McCune, Douglas Hanahan

The initiation and progression of sickle cell nephropathy

Overexpression of Wild-type p53 in Lichen Sclerosus adjacent to Human Papillomavirus-negative Vulvar Cancer Katrina Vanin, James Scurry, Heather Thorne,

Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J

C/EBPα Expression Is Downregulated in Human Nonmelanoma Skin Cancers and Inactivation of C/EBPα Confers Susceptibility to UVB-Induced Skin Squamous Cell.

This month in Gastroenterology

Volume 6, Issue 3, Pages (September 2004)

A Phase III Randomized Trial of Gemcitabine–Oxaliplatin versus Carboplatin–Paclitaxel as First-Line Therapy in Patients with Advanced Non-small Cell Lung.

Neal S Goldstein, MD The Annals of Thoracic Surgery

Slug/Snai2 Is a Downstream Mediator of Epidermal Growth Factor Receptor-Stimulated Reepithelialization Donna F. Kusewitt, Changsun Choi, Kimberly M.

Joan L. Walker, M.D. Stephenson Cancer Center University of Oklahoma

TFAP2A is highly expressed in nasopharyngeal carcinoma cells and tumor tissues. TFAP2A is highly expressed in nasopharyngeal carcinoma cells and tumor.

Socially isolated SV40 Tag mice develop significantly larger mammary gland tumors. Socially isolated SV40 Tag mice develop significantly larger mammary.

LINC00092 binds with PFKFB2 to promote ovarian cancer metastasis.

IL-13Rα2 expression is associated to human colon cancer progression and poor survival of patients with colorectal cancer. IL-13Rα2 expression is associated.

Endothelial cells/microvasucles are increased in prostate cancer versus normal tissues. Endothelial cells/microvasucles are increased in prostate cancer.

Antitumor effects of celastrol in vitro and in vivo.

Phase I Study of Induction Chemotherapy and Concomitant Chemoradiotherapy with Irinotecan, Carboplatin, and Paclitaxel for Stage III Non-small Cell Lung.

Effect of MZ treatment on lung colony formation in an experimental metastasis. Effect of MZ treatment on lung colony formation in an experimental metastasis.

Long-Term Follow-Up of a Phase I/II Trial of Dose Escalating Three-Dimensional Conformal Thoracic Radiation Therapy with Induction and Concurrent Carboplatin.

Combining IGF1R inhibitors with MEK or RAF inhibitors enhances the differential impact upon mutant KRAS cells. Combining IGF1R inhibitors with MEK or RAF.

Volume 14, Issue 2, Pages (August 2008)

Presentation transcript:

Focus on epithelial ovarian cancer Robert F. Ozols, Michael A. Bookman, Denise C. Connolly, Mary B. Daly, Andrew K. Godwin, Russell J. Schilder, Xiangxi Xu, Thomas C. Hamilton Cancer Cell Volume 5, Issue 1, Pages 19-24 (January 2004) DOI: 10.1016/S1535-6108(04)00002-9

Figure 1 Ovarian tumors in Tg-MISIIR-TAg mice A and B: H&E staining (A) and immunohistochemical detection (B) of large T antigen (TAg) protein of the ovarian carcinoma of a Tg-MISIIR-TAg transgenic mouse. C and D: Magnetic resonance images (MRI) of age-matched wild-type and Tg-MISIIR-TAg transgenic mice. The normal ovary of the wild-type mouse is indicated by the arrow in C and the ovarian tumors are indicated by the arrows in D. Images were acquired with a 2D spin-echo pulse sequence, TR = 1200 msec, TE = 13 msec, and 4 averages were acquired in a dedicated animal MRI scanner at a field strength of 7 Tesla for a total imaging time of 19 min. Prior to imaging, the mice received an intramuscular injection of the contrast agent Gd-DTPA. Cancer Cell 2004 5, 19-24DOI: (10.1016/S1535-6108(04)00002-9)

Figure 2 Progression-free and overall survival for advanced ovarian cancer Survival (upper curves) and progression-free survival (lower curves) for 790 stage III ovarian cancer patients following optimal cytoreduction (no tumor nodule >1 cm) and treatment with either cisplatin plus paclitaxel or carboplatin plus paclitaxel (GOG 158, Ozols et al., 2003). While median survival is almost five years, time to progression is less than two years. Median survival after progression is two years. Cancer Cell 2004 5, 19-24DOI: (10.1016/S1535-6108(04)00002-9)